An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Clinical trial NCT02648997 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02648997
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-01
- Primary completion
- 2024-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.